Zai Lab (NASDAQ:ZLAB) CFO Yajing Chen Sells 5,199 Shares

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 5,199 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $20.39, for a total value of $106,007.61. Following the sale, the chief financial officer owned 32,558 shares of the company’s stock, valued at approximately $663,857.62. This represents a 13.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Yajing Chen also recently made the following trade(s):

• On Friday, March 13th, Yajing Chen sold 1,703 shares of Zai Lab stock. The shares were sold at an average price of $18.63, for a total value of $31,726.89.

Zai Lab Price Performance

Shares of NASDAQ:ZLAB remained flat at $20.41 on Friday. The stock had a trading volume of 707,427 shares, compared to its average volume of 746,471. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -12.68 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a twelve month low of $15.96 and a twelve month high of $44.34. The business has a 50-day moving average of $18.63 and a 200 day moving average of $21.91.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%.The company had revenue of $127.60 million for the quarter. As a group, equities analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZLAB. Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. UBS Group started coverage on shares of Zai Lab in a research report on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a research note on Wednesday, January 21st. Zacks Research lowered shares of Zai Lab from a “hold” rating to a “strong sell” rating in a report on Friday, January 23rd. Finally, Cantor Fitzgerald decreased their price objective on Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zai Lab presently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Institutional Investors Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC grew its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.